Procainamide

Note: This product is not licenced in Australia at the time of publication. The information in this monograph applies to the specified brand, formulation and strength only.

Trade name

Procainamide (Hospira)

Strength

100 mg/mL (volume: 10 mL)

500 mg/mL (volume: 2 mL)

IV administration

For loading dose, dilute to 20 mg/mL and infuse according to age:

Neonates: 1 hour.

Infants and children: 30 minutes to 1 hour.

Adolescents: 20 to 50 mg/minute.

For continuous infusion, dilute to 2 to 4 mg/mL in a compatible fluid.

Other routes of administration

IM: Suitable. Give undiluted.

SC: Not recommended.

Compatible IV fluids

Glucose 5%

Sodium chloride 0.9%

Additional information

Contains sulfites. Observe closely for anaphylactic reactions.

Complex medication management; seek specialist advice.

Rapid administration may cause severe hypotension.

Continuous cardiac monitoring required. Use only when facilities for cardiac monitoring and cardio-respiratory resuscitation exist.

Therapeutic Drug Monitoring may be required; refer to local guidelines.

Solution should be clear and colourless or slightly yellow. Discard if darker than amber.

Discard any unused vial contents.